Novel Dehydroepiandrosterone Derivatives with Antiapoptotic, Neuroprotective Activity

Novel Dehydroepiandrosterone Derivatives with Antiapoptotic, Neuroprotective Activity

URI: https://www.openarchives.gr/aggregator-openarchives/edm/helios/000024-10442_12230
RDF/XML JSON-LD

This item is provided by the institution :
National Hellenic Research Foundation (NHRF)

Repository :
Helios - Repository of the National Hellenic Research Foundation (NHRF) | repositories EKT

see the original item page
in the repository's web site and access all digital files if the item^*

Title

Novel Dehydroepiandrosterone Derivatives with Antiapoptotic, Neuroprotective Activity

Creator

Pantzou, Athanasia

Vergou, Varvara

Charalampopoulos, Ioannis

Avlonitis, Nicolaos

Alexi, Xanthippi

Minas, Vassilios

Gravanis, Achille

Zervou, Maria

Lazaridis, Iakovos

Alexis, Michael N.

Katsanou, Efrosini S.

Description

DHEA analogues with modifications at positions C3 or 07 were synthesized and evaluated for neuroprotective activity against the neural-crest-derived PC12 cell model of serum deprivation-induced apoptosis. The most potent compounds were the spiro-epoxy derivatives 17 beta-spiro[5-androstene-17, 2'-oxiran]-3 beta-ol (20), (20S)-3 beta,21-dihydroxy-17 beta,20-epoxy-5-pregnene (23), and (20R)-3 beta,21-dihydroxy-17 alpha,20-epoxy-5-pregnene (27) with IG(50) values of 0.19 +/- 0.01, 99.0 +/- 4.6, and 6.4 +/- 0.3 nM, respectively. Analogues 20, 23, and 27, up to the micromolar range of concentrations, were unable to activate estrogen receptor alpha and beta (ER alpha and ER beta) or to interfere with ER-dependent gene expression significantly. In addition, they were unable to stimulate the growth of Ishikawa, MCF-7, and LNCaP cells. Our results suggest that the spiro-epoxyneurosteroid derivatives 20, 23, and 27 may prove to be lead molecules for the synthesis of novel neuroprotective agents.

Type

Article